CoMentis (Drug Discovery) Overview
- Year Founded
-
2004
- Status
-
Out of Business
- Employees
-
33
- Latest Deal Type
-
Liquidation
CoMentis (Drug Discovery) General Information
Description
Developer of small-molecule drugs designed to treat central nervous system disorders. The company's drugs cover the research and development spectrum from initial drug design through manufacturing and clinical trials, enabling healthcare professionals to treat age-related macular degeneration (AMD) and other cognitive disorders easily.
Contact Information
Website
www.comentis.comCorporate Office
- 400 Oyster Point Boulevard
- Suite 226
- South San Francisco, CA 94080
- United States
Corporate Office
- 400 Oyster Point Boulevard
- Suite 226
- South San Francisco, CA 94080
- United States
CoMentis (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Bankruptcy: Liquidation | 01-Jun-2017 | Completed | Out of Business | |||
| 5. Later Stage VC (Series E) | 16-Mar-2016 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series D) | 15-May-2008 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 24-Oct-2007 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 06-Sep-2007 | $50M | $71M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 11-Aug-2006 | $21M | $21M | Completed | Generating Revenue |
CoMentis (Drug Discovery) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 92,543,030 | $0.000100 | 8.5% | $0.43 | $0.43 | 1x | $0.43 | 37.51% |
| Series A | 34,669,123 | $0.000100 | 8.5% | $0.47 | $0.47 | 1x | $0.47 | 14.05% |
CoMentis (Drug Discovery) Comparisons
Industry
Financing
Details
CoMentis (Drug Discovery) Competitors (50)
One of CoMentis (Drug Discovery)’s 50 competitors is Promentis Pharmaceuticals, a Venture Capital-Backed company based in Milwaukee, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Promentis Pharmaceuticals | Venture Capital-Backed | Milwaukee, WI | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Mitochon Pharmaceuticals | Venture Capital-Backed | Blue Bell, PA | ||||
| Metabolic Solutions Development Company | Venture Capital-Backed | Kalamazoo, MI | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA |
CoMentis (Drug Discovery) Patents
CoMentis (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2013267555-A1 | Chromane compounds | Inactive | 30-May-2012 | ||
| CA-2873678-A1 | Chromane compounds | Inactive | 30-May-2012 | ||
| EP-2854797-A2 | Chromane compounds | Inactive | 30-May-2012 | ||
| EP-2854797-A4 | Chromane compounds | Inactive | 30-May-2012 | ||
| US-20140179695-A1 | Chromane compounds | Active | 30-May-2012 | C07D413/14 |
CoMentis (Drug Discovery) Signals
CoMentis (Drug Discovery) Investments & Acquisitions (3)
CoMentis (Drug Discovery)’s most recent deal was a Early Stage VC with Soyhuce for . The deal was made on 01-May-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Soyhuce | 01-May-2017 | Early Stage VC | IT Consulting and Outsourcing | ||
| Zapaq | 14-Aug-2006 | Merger/Acquisition | Drug Discovery | ||
| Osprey Pharmaceutical Company | 13-Apr-2006 | Merger/Acquisition | Drug Discovery |
CoMentis (Drug Discovery) FAQs
-
When was CoMentis (Drug Discovery) founded?
CoMentis (Drug Discovery) was founded in 2004.
-
Where is CoMentis (Drug Discovery) headquartered?
CoMentis (Drug Discovery) is headquartered in South San Francisco, CA.
-
What is the size of CoMentis (Drug Discovery)?
CoMentis (Drug Discovery) has 33 total employees.
-
What industry is CoMentis (Drug Discovery) in?
CoMentis (Drug Discovery)’s primary industry is Drug Discovery.
-
Is CoMentis (Drug Discovery) a private or public company?
CoMentis (Drug Discovery) is a Private company.
-
What is CoMentis (Drug Discovery)’s current revenue?
The current revenue for CoMentis (Drug Discovery) is .
-
How much funding has CoMentis (Drug Discovery) raised over time?
CoMentis (Drug Discovery) has raised $108M.
-
Who are CoMentis (Drug Discovery)’s competitors?
Promentis Pharmaceuticals, Genentech, Mitochon Pharmaceuticals, Metabolic Solutions Development Company, and Alzheon are some of the 50 competitors of CoMentis (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process